Keyphrases
Methotrexate Clearance
100%
Isavuconazonium Sulfate
100%
Letermovir
100%
Cytomegalovirus Prevention
100%
Philadelphia Chromosome
100%
Transplant Population
100%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
100%
Acute Kidney Injury
100%
Pediatric Oncology
100%
Imatinib
100%
Hematopoietic Cell Transplantation
100%
Stem Cell Transplantation
100%
Retrospective Review
100%
High-dose Methotrexate (HD-MTX)
100%
Pediatric Patients
100%
Adolescent Patients
100%
Single Institution
100%
Tyrosine Kinase Inhibitor
33%
Invasive Fungal Disease
33%
Cytomegalovirus
20%
Clinically Significant
20%
Cytomegalovirus Prophylaxis
20%
Cytomegalovirus Infection
20%
Hyperhydration
16%
First Cycle
16%
Clinical Toxicity
16%
CARE Measure
16%
Improved Survival
16%
Therapy Discontinuation
16%
Clinical Efficacy
16%
Drug Interactions
16%
Glucarpidase
16%
Invasive mucormycosis
16%
Methotrexate
16%
No Adverse Effect
16%
Triazole Antifungal Agents
16%
Withholding
16%
Short Hospitalization
16%
Single Center
16%
Supportive Care
16%
Invasive Aspergillosis
16%
Transplant Patients
16%
Acute Lymphoblastic Leukemia
16%
Delayed Clearance
16%
Pharmacology, Toxicology and Pharmaceutical Science
Philadelphia 1 Chromosome
100%
Acute Kidney Failure
100%
Acute Lymphoblastic Leukemia
100%
Letermovir
100%
Isavuconazonium
100%
Imatinib
100%
Childhood Cancer
100%
Methotrexate
100%
Cytomegalovirus
100%
Mycosis
33%
Protein Tyrosine Kinase Inhibitor
25%
Cytomegalovirus Infection
20%
Invasive Aspergillosis
16%
Mucormycosis
16%
Triazole
16%
Drug Interaction
12%
Carboxypeptidase G2
12%